Loading
Loading
Research Overview
Splice variant of IGF-1 produced locally by skeletal muscle in response to mechanical loading; E-domain peptide activates quiescent satellite cells (muscle stem cells) to proliferate and fuse with damaged fibres via a receptor-independent mechanism distinct from classic IGF-1R signalling.
MGF (Mechano Growth Factor) is a splice variant of IGF-1 produced locally by muscle tissue in response to mechanical loading or damage. Unlike systemic IGF-1, MGF acts as a localised signal that activates satellite cells — the muscle stem cells responsible for repair and hypertrophy — making it a subject of intense research interest in muscle biology and post-injury recovery contexts.
The native, unmodified form of MGF is characterised by an extremely short half-life of approximately 5–7 minutes, as it is rapidly cleared by serum proteases. This rapid degradation restricts its action to the local tissue environment, which is thought to be central to its physiological role. PEG-MGF, a pegylated derivative, was developed specifically to extend this half-life for systemic research applications, and the two peptides are frequently compared in preclinical studies.
Research into MGF has focused on its E-domain peptide sequence — a unique 24-amino-acid region absent in other IGF-1 splice variants — which appears to be responsible for satellite cell activation independently of the IGF-1 receptor pathway. This mechanistic distinction has made MGF a model compound for understanding localised muscle anabolism and repair signalling.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, mgf (mechano growth factor) peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
MGF (Mechano Growth Factor) Peptide research is most relevant to protocols examining:
Researchers studying localised satellite cell activation and muscle repair biology
Muscle biology investigations into post-injury tissue remodelling
Studies comparing unmodified MGF versus PEG-MGF in site-specific anabolic signalling
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~5–7 minutes (unmodified; rapidly cleared by serum proteases)). Review data, confirm baseline recovery before any repeat protocol.
Splice variant of IGF-1 produced locally by skeletal muscle in response to mechanical loading; E-domain peptide activates quiescent satellite cells (muscle stem cells) to proliferate and fuse with damaged fibres via a receptor-independent mechanism distinct from classic IGF-1R signalling.
| Parameter | Value |
|---|---|
| Dose range | 100–200 mcg post-workout, subcutaneous near trained muscle |
| Schedule | Post-workout, once daily |
| Route | Subcutaneous |
| Half-life | ~5–7 minutes (unmodified; rapidly cleared by serum proteases) |
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.